Abstract

ObjectiveTo predict the sensitivity of nasopharyngeal carcinoma (NPC) to neoadjuvant chemotherapy (NACT) based on magnetic resonance (MR) radiomics and clinical nomograms prior to NACT.Materials and MethodsFrom January 2014 to July 2015, 284 consecutive patients with pathologically confirmed NPC underwent 3.0 T MR imaging (MRI) before initiating NACT. The patients’ data were randomly assigned to a training set (n = 200) or a test set (n = 84) at a ratio of 7:3. The clinical data included sex, tumor (T) stage, lymph node (N) stage, American Joint Committee on Cancer (AJCC) stage, and the plasma concentration of Epstein–Barr virus (EBV) DNA. The regions of interest (ROI) were manually segmented on the axial T2-weighted imaging (T2WI) and enhanced T1-weighted imaging (T1WI) sequences using ITK-SNAP software. The radiomics data were post-processed using AK software. Moreover, the Maximum Relevance Minimum Redundancy (mRMR) algorithm and the Least Absolute Shrinkage and Selection Operator (LASSO) were adopted for dimensionality reduction to screen for the features that best predicted the treatment efficacy, and clinical risk factors were used in combination with radiomics scores (Rad-scores) to construct the clinical radiomics-based nomogram. DeLong’s test was utilized to compare the area under the curve (AUC) values of the clinical radiomics-based nomogram, radiomics model, and clinical nomogram. Decision curve analysis (DCA) was employed to evaluate each model’s net benefit.ResultsThe clinical nomogram was constructed based on data from patients who were randomly assigned according to T2WI and enhanced T1WI sequences. In the training set, the T2WI sequence-based clinical radiomics nomogram and the radiomics model outperformed the clinical nomogram in predicting the NACT efficacy (AUC, 0.81 vs. 0.60, p = 0.001279 and 0.76 vs. 0.60, p = 0.03026). These findings were well-verified in the test set. The enhanced T1WI sequence-based clinical radiomics nomogram exhibited better performance in predicting treatment efficacy than the clinical nomogram (AUC, 0.79 vs. 0.62, respectively; p = 0.0000834). The DCA revealed that the T2WI and clinical radiomics-based nomograms resulted in a net benefit in predicting the NACT efficacy.ConclusionThe clinical radiomics-based nomogram improved the prediction of NACT efficacy, with the T2WI sequence-based clinical radiomics achieving the best effect.

Highlights

  • Radiotherapy is the main treatment for nasopharyngeal carcinoma (NPC), which is associated with a complicated anatomical structure

  • Recent studies have shown that NPC survival is related to the clinical tumor, node, metastasis (TNM) stage, the plasma levels of Epstein-Barr virus (EBV) DNA, the EBV antibody levels evaluated by assays, the lactic dehydrogenase (LDH) and hemoglobin (HGB) levels, the platelet count (PLT), and the lymphocyte (LYM) and neutrophil (NEUT) ratios

  • There were no significant differences in terms of sex, T stage, American Joint Committee on Cancer (AJCC) stage, plasma EBV-DNA levels, Rta protein immunoglobulin G antibody (RtaIgG), viral capsid antigen immunoglobulin A antibody (VCAIgA), early antigen immunoglobulin A antibody (EA-IgA), and HGB levels or PLT counts between the response group and nonresponse group in the training set or test set

Read more

Summary

Introduction

Radiotherapy is the main treatment for nasopharyngeal carcinoma (NPC), which is associated with a complicated anatomical structure. To reduce the likelihood of local recurrence and distant metastasis (DM) of NPC, chemotherapy in combination with radiotherapy is the main recommendation at present [4]. The administration of NACT prior to concurrent chemotherapy can improve the disease-free survival (DFS) and overall survival (OS) of patients with NPC [9]. The early prediction of a patient’s response to NACT is of crucial importance, as it assists clinicians in formulating suitable therapeutic regimens before treatment and minimizes unnecessary chemotherapy-induced toxicity. When evaluating the therapeutic effect of a treatment for NPC, the aforementioned functional MR technologies assess the tumor mass from the level of interest, rather than from the overall mass, and there are differences in the parameters measured by different equipment. NPC survival is closely related to a patient’s sensitivity to chemotherapeutic agents and radiotherapy [13], while tumor heterogeneity is related to tumor invasion and resistance [14]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.